Free Trial
NASDAQ:ENTX

Entera Bio Q1 2025 Earnings Report

Entera Bio logo
$1.80 0.00 (0.00%)
As of 09/19/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Entera Bio EPS Results

Actual EPS
-$0.06
Consensus EPS
-$0.07
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Entera Bio Revenue Results

Actual Revenue
$0.04 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Entera Bio Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Friday, May 9, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Entera Bio's Q3 2025 earnings is scheduled for Friday, November 14, 2025, with a conference call scheduled on Friday, November 7, 2025 at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Entera Bio Earnings Headlines

A New Way to Double Your Retirement Income?
Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boom. For retirees, that could mean a way to generate reliable monthly income—without the outdated 4% withdrawal rule, risky trading, or high-fee annuities. If you’re ready to stop worrying about money running out and start enjoying the freedom to cover expenses, treat loved ones, and live life on your terms, this may be exactly what you’ve been waiting for.tc pixel
See More Entera Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Entera Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Entera Bio and other key companies, straight to your email.

About Entera Bio

Entera Bio (NASDAQ:ENTX), Inc. is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis. EB613 entered Phase 1 clinical trials to assess safety, tolerability and pharmacokinetics in healthy volunteers. In parallel, Entera Bio is advancing EB612, an oral tumor necrosis factor (TNF) antagonist, toward early‐stage clinical development for inflammatory diseases such as rheumatoid arthritis and Crohn’s disease.

Since its founding in 2010, Entera Bio has established operations in Newton, Massachusetts, and research facilities in Israel, positioning the company at the intersection of North American and international biopharmaceutical innovation. Its leadership team combines expertise in peptide chemistry, clinical development, regulatory affairs and commercial strategy. Entera Bio plans to collaborate with established pharmaceutical partners to support late‐stage clinical programs and the global commercialization of its oral peptide product candidates.

View Entera Bio Profile

More Earnings Resources from MarketBeat